Montpellier

• A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea … Ended recruitment
  2023-510357-42-00 5 2019-05-22 hormone receptor (HR)-positive, HER2-negative, early breast cancer (EB
• Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer Ended recruitment
  2024-512165-13-00 4 2019-05-13 Localised unresectable adenocarcinoma or squamous cell carcinoma of th
• This is a Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatmen … Ended recruitment
  2023-510015-19-00 5 2019-02-11 Patients with histologically or cytologically documented muscle-invasi
• Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN) Ended recruitment
  2023-505495-30-00 5 2019-02-01 Immunoglobulin A Nephropathy (IgAN)
• Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended recruitment
  2023-506921-12-00 5 2018-12-27 ER+/HER2- Breast Cancer
• The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study Ended recruitment
  2024-510605-28-00 5 2018-11-27 Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
• START : Study on Androgen Receptor and Triple Negative Breast Cancer Ended recruitment
  2024-516638-36-00 4 2018-03-14 Triple-negative androgen receptor positive (molecular apocrine-like HE
• Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, … Ended recruitment
  2024-512470-10-00 11 2018-02-02 End-stage Renal disease
• Randomized trial of avelumab-cetuximab-Radiotherapy versus standards of care in the head and neck cancers Ended recruitment
  2024-513964-24-00 5 2017-09-14 Squamous cell carcinoma, previously untreated Stage III, stage IVa (op
• Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (PANIRINOX) Ended recruitment
  2024-510645-34-00 4 2017-06-28 RAS and B-RAF wild-type metastatic colorectal cancer. RAS and B-RAF mu
• IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting Ended recruitment
  2024-517489-41-00 5 2017-03-27 High-risk stage III colon cancer
• eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients Ended recruitment
  2024-513454-29-00 5 2015-10-15 Non-Small Cell Lung Cancer (NSCLC)
• Treatment protocol for osteosarcomas in children, adolescents and adults including a randomized trial and biological studies Ended recruitment
  2024-514756-32-00 5 2007-03-19 High grade osteosarcoma
• Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients with Cystic Fibrosis Halted
  2024-511184-28-00 4 2024-10-23 Cystic fibrosis
• Study of efficacy and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C- muta … Halted
  2024-511708-18-00 4 2022-12-06 Locally advanced or metastatic KRAS G12C-mutated non-small cell lung c
• A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety … Halted
  2024-516671-33-00 5 2021-05-24 Amyotrophic Lateral Sclerosis
• A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome Ended
  2023-507680-19-00 4 2024-11-28 Sjögren’s Syndrome
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole Compared to Letrozole Alone in Postmenopausal Wom … Ended
  2024-512848-30-00 4 2024-11-12 HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER
• Prospective and multicentre evaluation of 3 different doses of IV busulfan associated with fludarabine and thymoglobuline in the conditionin … Ended
  2024-516435-27-00 4 2024-11-05 High-risk myeloïd malignancies
• Vonafexor fixed dose-escalation safety and proof-of-concept study in patients with at risk of progression Alport syndrome Ended
  2023-509638-20-00 4 2024-09-30 Alport Syndrome
• A study of aficamten (CK-3773274) in adults with symptomatic non-obstructive hypertrophic cardiomyopathy (ACACIA) Ended
  2023-505797-15-00 5 2024-09-13 SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
• A Phase 1/2, Multicenter Study Evaluating the Safety, Tolerability, and Biodistribution of RCT2100 with Single-Ascending Doses in Healthy Pa … Ended
  2024-512169-15-00 7 2024-08-28 Cystic Fibrosis
• MK-0616 versus Comparators Study in Adults with Hypercholesterolemia Ended
  2023-504920-25-00 5 2024-08-23 Hypercholesterolemia
• A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i … Ended
  2023-506696-10-00 5 2024-06-18 Non-Small Cell Lung Cancer

Showing 217–240 of 273 trials